Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration Eisai May 08, 2023 10:15 HKT/SGT Read More
Asia's insurance leaders to gather at InsureTech Connect Asia in Singapore to discuss the future of insurance Clarion Events Ltd Apr 18, 2023 16:59 JST Read More
New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 NEC Corporation Apr 18, 2023 16:13 HKT/SGT Read More
アバンセ・クリニカルのCEOが2023年エボリューション・ヨーロッパ・サミットのグローバル・バイオファーマ・パネルに参加 Avance Clinical Apr 18, 2023 11:00 JST Read More
Eisai Completes a Major Renovation of Tsukuba Research Laboratories Eisai Apr 06, 2023 17:32 HKT/SGT Read More
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal Eisai Apr 04, 2023 12:23 HKT/SGT Read More
エーザイ、臨床第III相Clarity AD試験データを用いた「レカネマブ」の長期的健康アウトカムについて、シミュレーションを用いた評価結果が査読学術専門誌Neurology and Therapy誌に掲載 Eisai Apr 04, 2023 12:00 JST Read More
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System Eisai Apr 03, 2023 12:06 HKT/SGT Read More
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結 Eisai Apr 03, 2023 10:00 JST Read More
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting Eisai Mar 31, 2023 15:51 HKT/SGT Read More
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals Eisai Mar 31, 2023 13:55 HKT/SGT Read More
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business NEC Corporation Mar 31, 2023 09:14 HKT/SGT Read More
Fujitsu launches new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development Fujitsu Ltd Mar 28, 2023 09:17 HKT/SGT Read More
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer Eisai Mar 24, 2023 12:22 HKT/SGT Read More
エーザイ、米国婦人科腫瘍学会（SGO）2023 Annual Meeting on Women's Cancerにおいてオンコロジー領域の臨床研究の演題を発表 Eisai Mar 24, 2023 11:00 JST Read More
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting Eisai Mar 23, 2023 12:30 HKT/SGT Read More
エーザイ、第17回アルツハイマー・パーキンソン病学会（AD/PD 2023）において、レカネマブの安全性プロファイル、臨床結果、QOLの評価など、アルツハイマー病の研究に関する最新情報を発表 Eisai Mar 23, 2023 09:00 JST Read More
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal Eisai Mar 20, 2023 10:18 HKT/SGT Read More
